MedTrace Logo

RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

NCT04620655 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-11-09

No results posted yet for this study

Summary

This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.

Conditions

  • T Acute Lymphoblastic Leukemia
  • T-lymphoblastic Lymphoma

Interventions

DRUG

RD13-01 cell infusion

Universal CAR-T cells targeting CD7

Sponsors & Collaborators

  • Min Xiang

    lead OTHER

Principal Investigators

  • Xian Zhang · Hebei Yanda Ludaopei Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-15
Primary Completion
2021-11-15
Completion
2022-11-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04620655 on ClinicalTrials.gov